Skip to main content

Medical Injectables Program Updates

Horizon collaborates with Magellan Rx Management (MRxM) to administer its Medical Injectables Program (MIP). As part of our shared commitment to help ensure that the medications our members need are medically necessary and cost effective, the following changes will be made to our MIP.

  • Use New HCPCS Code for Istodax
    Based on Centers for Medicare & Medicaid Services’ (CMS) guidance, please use HCPCS code J9319 when submitting Prior Authorization & Medical Necessity Determination (PA/MND) requests and claims for Istodax® (romidepsin, lyophilized) for services provided on and after October 1, 2021.
  • Medical Necessity and Appropriateness Review
    Beginning with services provided on and after February 1, 2022, MRxM will conduct medical necessity and appropriateness reviews (MNAR) for the following injectable medications as part of the MIP.
Generic Medication Name HCPCS Code Medication Brand Name
casimersen J1426 Amondys 45™  
evinacumab-dgnb J1305 Evkeeza™  
melphalan flufenamide J9247 Pepaxto®  
romidepsin, non-lyophilized J9318 available as generic only  
trilaciclib J1448 Cosela™  

If you have any questions, please contact your Network Specialist or Ancillary Contracting Specialist.


  • As part of our MIP, MRxM conducts MNARs for injectable medications administered in a freestanding or hospital-based dialysis center, an outpatient facility, a patient’s home or a physician’s office. MRxM does not conduct MNARs for injectable medications administered during an inpatient stay, or in an Emergency Room or Observation Room setting.

    For medical Injectable services rendered in the patient’s home, call 1-855-243-3321 for participating Horizon Care@Home health care professionals to obtain pre-service determination.
  • We encourage you to review the medical policy criteria and guidelines for the injectable medications included as part of the MIP within our Medical Policy Manual.

Magellan Rx Management℠ is a service mark of Magellan Health, Inc. Magellan Rx Management is an independent company that supports Horizon Blue Cross Blue Shield of New Jersey in the administration of conduct medical necessity and appropriateness review (MNAR) for certain medical injectable drugs. Magellan Rx Management is independent from and not associated with Horizon Blue Cross Blue Shield of New Jersey.

This web page contains prescription brand name drugs that are registered marks or trademarks of pharmaceutical manufacturers that are not affiliated with Magellan Rx Management, Horizon Blue Cross Blue Shield of New Jersey or the Blue Cross Blue Shield Association.

Published on: November 1, 2021, 12:01 p.m. ET
Last updated on: October 29, 2021, 03:55 a.m. ET